October 1, 2026
Weight Watchers announced a collaboration with Google Health Enterprise, combining wearable technology and AI-powered health insights with Weight Watchers’ clinical weight health program. Available now through select Weight Watchers for Business client programs, this collaboration provides employers and payers a new way to activate their weight health benefits, helping more members get started, stay engaged and build the daily habits that support better outcomes.
According to management: “As employers and payers navigate this new landscape, they need a partner that supports members at every step of their weight health journey—from creating a program experience that drives daily engagement to providing tailored clinical care that meets their unique needs,” said Scott Honken, PharmD, Chief Commercial Officer, Weight Watchers. “Our collaboration with Google Health expands access and strengthens connection across that journey, complementing personalized experiences like our GLP-1 Success Program and Med+ virtual clinic to help deliver the outcomes clients count on and members expect.”
Highlights of the collaboration include:
- Access to Google Fitbit Air and Google Health Premium1 for eligible Weight Watchers for Business clients and members after completing required activity and duration milestones.
- A more connected experience that allows members to connect a Fitbit Air to their Weight Watchers account and access additional insights around activity, sleep, and health.
- More comprehensive tracking on and off the scale, helping members see progress through daily movement and other health signals that can reinforce long-term behavior change.
The company explained that participants in select employer-sponsored programs can connect the wearable devices directly to their accounts to track physical activity, sleep, and other health metrics. WW International noted that the integration of wearable technology and artificial intelligence insights aims to support habit building and overall health management for participating members.
Commentary
Rising consumer use of GLP-1 weight-loss drugs is still pressuring demand for its legacy behavioral diet programs. There was a brief 9%–12% jump in WW stock price during the Sept. 29 session on the WeightWatchers–Google Health Enterprise collaboration: eligible members in select employer programs can get Fitbit Air wearables and AI-driven health insights tied to Weight Watchers plans.
However, that stock price jump was short-lived. That tech tie-up supports engagement in the GLP-1 era, but it does not erase the structural hit to traditional behavioral subscriptions as medication-led weight loss gains share. The fact remains that most of WW revenues (76% as of the Q2 2026 performance press release on August 5) still comes from non-medical programs. Investors appear to be treating the Google news as incremental while staying focused on that longer-run demand shift.
WW’s shares are volatile and have had 79 moves greater than 5% over the last year. The recent move down indicates that the market considers this news meaningful but not something that would fundamentally change its perception of the business.
Learn More About The Commercial & Medical Weight Loss Market – Marketdata LLC Reports
Marketdata LLC’s March 2026 report: “The U.S. Weight Loss Market: Status Report & 2026 Forecast” This 108-page analysis tracks the current status of ALL weight loss market segments, 2025 performance, the latest dieting trends, 15 competitor profiles, with 27 tables and charts.
Some findings:
- The total U.S. weight loss market was worth $135 billion in 2025 (when including the revenues of health clubs ). A 6.6% increase is forecast in 2026, largely due to growing sales of GLP-1 drugs.
- Commercial weight loss companies/centers (Weight Watchers, NutriSystem, jenny Craig, Medifast) saw revenues fall by 24% as a group in 2025, to $1.86 billion, as they struggle to pivot and deal with strong competition from the GLP-1 drugs.
- All medical programs accounted for a new high of 38% of the total market, worth $51.5 billion last year. This is up sharply from 11% in 2022, prior to the GLP-1 drugs boom.
- The number of bariatric surgeries is estimated to have fallen by 8% in 2024 and another 6% in 2025, to 232,000.
- The market for prescription obesity medications is estimated to have increased by 64%, to $43.48 billion. Growth will be slower in 2026, as new and cheaper weight loss pills enter the market.
- Meal replacements and OTC appetite suppressants is a $4.2 billion market. Shakes and nutrition bars have held up well but retail diet pills sales are plummeting.
The complete report is available for sale, for $995, at: marketdataenterprises.com, or by calling Marketdata at: 813-971-8080. A Table of Contents can be found at the website.
Note: Marketdata’s specialty for 37 years since 1989 has been the weight loss market, with 50+ published in-depth studies, custom research projects and consulting.
The report includes in-depth analyses of: 2024-2025 market/revenue performance, recent competitor and market developments, current dieter trends and top diet plans, and diet company advertising and marketing spending. Special emphasis and analysis of the obesity drugs market and its effect on all market segments. Coverage of cheaper compounded drugs that are not FDA-approved, new drugs entering the market.
Individual Status Reports and the effects of the obesity drugs boom on operations and revenues, for ALL major weight loss market segments… diet soft drinks, artificial sweeteners, health clubs industry, commercial weight loss chains, retail meal replacements and appetite suppressants, and low-calorie dinner entrees.
Includes profiles and 2025 performance of: Medifast, Weight Watchers, NutriSystem, Slim-Fast, Simply Good Foods (Atkins) Herbalife, AMWAY, Premier Protein, Eli Lillky, Novo Nordisk and Noom.
Buy This Report: Call 813-971-8080 and charge it or order online for instant download at: www.marketdataenterprises.com.